Connect with us
MARE BALTICUM Gaming & TECH Summit 2024

Fintech PR

Thatcham Research Selects LexisNexis Risk Solutions to Deliver Transformational Automotive Risk Intelligence to the U.K. Insurance Industry




Data Leader Brings Speed, Automation, Consistency to Industry’s Integral Motor Risk Assessment and Rating Data

LONDON, March 5, 2024 /PRNewswire/ — In a major development for the U.K. insurance industry, LexisNexis® Risk Solutions, the data, advanced analytics and technology provider, has secured an exclusive strategic relationship with Thatcham Research, in the first contract of its kind with the insurer-funded automotive risk intelligence company. The strategic relationship is set to transform the accessibility, consistency and analytical power of Thatcham Vehicle Risk Data (VRD)i which is used to assign an industry-standard ABI Code and Group Rating score to vehicles. The VRD is integral to how insurers assess and rate risk for all wheels-based insurance products.

The news comes as the Association of British Insurers, in close collaboration with Thatcham Research, has released its motor insurance affordability roadmapii. This includes recommendations to increase visibility of the Group Rating system, which would help consumers make more informed choices on their motor insurance based on the vehicle they choose. This collaboration will help support these actions and recommendations, making it easier for insurance providers to be transparent with customers over vehicle ratings as car safety technology evolves.

  • The first element of the agreement focuses on streamlining and automating access to the VRD. LexisNexis Risk Solutions has the widest data distribution network into the U.K. insurance sector, streamlining data directly into insurers, brokers, managing general agents (MGAs), insurtechs, software houses and third-party data providers, to support billions of insurance quotes per month. LexisNexis Risk Solutions will become the sole distributor of Thatcham VRD to the U.K. and ROI insurance market.

    Leveraging this unique network, insurance providers, including insurers, brokers, MGAs, insurtechs and software houses, will be able to access Thatcham VRD in real time for the first time, alongside additional public, third party and proprietary data sources, as part of a streamlined risk assessment and decisioning process, via the LexisNexis® Informed Quotes platform.

  • The second element of the agreement focuses on consistent matching of Thatcham VRD to vehicle registrations. As part of the strategic relationship with Thatcham Research, LexisNexis Risk Solutions will use its extensive linking and data normalisation expertise to match vehicles to Thatcham VRD (incorporating the Group Rating, Variant Code and ABI Code datasets). This will create greater consistency for insurance providers by delivering more granular data to support the identification of risk-affecting vehicle features in the quoting process regardless of the quoting platform.
  • The third element of the agreement will focus on uncovering new, predictive vehicle intelligence. Leveraging its long track record of building new and innovative vehicle data products, LexisNexis Risk Solutions will collaborate with Thatcham Research in exploring the possibility to unlock significant intelligence on vehicles that does not exist today.

James Burton, managing director, U.K. and Ireland insurance, LexisNexis Risk Solutions, said: “We pride ourselves on being experts in insurance, and our vehicle strategy is both consistent with and complementary to the Thatcham Research vision. This strategy makes LexisNexis Risk Solutions well-placed to unlock the potential in the Thatcham VRD product, creating transformational insights for motor insurance providers. As an organisation, we are passionate, driven by the opportunity to help Thatcham Research customers, our customers and our shared customers realise the benefits of this relationship as they look to improve profitability, operational efficiency, reduce claims costs and improve the customer experience.”

Jonathan Hewett, chief executive of Thatcham Research, said: “This exclusive relationship with LexisNexis Risk Solutions will allow Thatcham Research to focus efforts on research, testing and training, knowing that the insights we offer that are essential to how insurance providers derive premiums and assess risk will be managed by a trusted partner to the industry. We are pleased to be able to offer insurance providers greater access to vital data which may not have been accessible previously. The combination of Thatcham Research and LexisNexis Risk Solutions assets and intelligence is compelling, providing an exciting roadmap for new services and insights that will improve the overall motor insurance customer experience.”

Visit our website to learn more about the strategic partnership between LexisNexis Risk Solutions and Thatcham Research.

About LexisNexis Risk Solutions

LexisNexis® Risk Solutions harnesses the power of data, sophisticated analytics platforms and technology solutions to provide insights that help businesses across multiple industries and governmental entities reduce risk and improve decisions to benefit people around the globe. Headquartered in metro Atlanta, Georgia, we have offices throughout the world and are part of RELX (LSE: REL/NYSE: RELX), a global provider of information-based analytics and decision tools for professional and business customers. For more information, please visit and

About Thatcham Research

Thatcham Research is the automotive risk intelligence company dedicated to understanding the opportunities and risks of new vehicle technology and supporting our partners in identifying the best strategies for its safe, secure, and sustainable adoption.

The independent voice of automotive safety, security, and repair, we work in close partnership with insurers, vehicle manufacturers, technology providers and government, providing rigorous engineering-grade research and data to help minimise uncertainty presented by changes in technology and regulation.

For more information about our work, visit

Media Contacts:
Alison Reeson or Matthew Enderby at HSL for LexisNexis Risk Solutions
0208 977 9132, 07876 597466
[email protected]

Annalysce Baker
Manager, Global Communications
Insurance and Connected Car
LexisNexis Risk Solutions
[email protected] 

Tom Flisher, Stewart Mitchell or Max Norstrom for Thatcham Research
07876 755 615
[email protected] 

Thatcham Research Vehicle Risk Data is a live and extensive, industry-standard dataset that contains key information about insurable cars, LCVs and motorcycles. Thatcham Research is solely responsible for maintaining this dataset with each vehicle containing more than 100 individual data points.

Using data exclusively supplied by vehicle manufacturers and checked by Thatcham Research’s expert data team, each vehicle is assigned a unique eight-digit ABI identification code. This translates into a standardised description of the vehicle that is used by the entire insurance industry.

Directly sourced data is also used to generate a Group Rating score for every vehicle. Ranging between 1 and 50 for cars and 21 to 50 for LCVs, scores indicate the level of insurance risk associated with the vehicle.


Jonathan Hewett, chief-executive, Thatcham-Research and James Burton, managing director, U.K. and Ireland insurance, LexisNexis Risk Solutions.


Thatcham Research

Logo –
Photo –
Photo –

Cision View original content:

Continue Reading
Click to comment

Leave a Reply

Your email address will not be published. Required fields are marked *

Fintech PR

Invitation to presentation of EQT AB’s Q1 Announcement 2024




STOCKHOLM, April 5, 2024 /PRNewswire/ — EQT AB’s Q1 Announcement 2024 will be published on Thursday 18 April 2024 at approximately 07:30 CEST. EQT will host a conference call at 08:30 CEST to present the report, followed by a Q&A session.

The presentation and a video link for the webcast will be available here from the time of the publication of the Q1 Announcement.

To participate by phone and ask questions during the Q&A, please register here in advance. Upon registration, you will receive your personal dial-in details.

The webcast can be followed live here and a recording will be available afterwards.

Information on EQT AB’s financial reporting

The EQT AB Group has a long-term business model founded on a promise to its fund investors to invest capital, drive value creation and create consistent attractive returns over a 5 to 10-year horizon. The Group’s financial model is primarily affected by the size of its fee-generating assets under management, the performance of the EQT funds and its ability to recruit and retain top talent.

The Group operates in a market driven by long-term trends and thus believes quarterly financial statements are less relevant for investors. However, in order to provide the market with relevant and suitable information about the Group’s development, EQT publishes quarterly announcements with key operating numbers that are relevant for the business performance (taking Nasdaq’s guidance note for preparing interim management statements into consideration). In addition, a half-year report and a year-end report including financial statements and further information relevant for investors is published. Finally, EQT also publishes an annual report including sustainability reporting.

Olof Svensson, Head of Shareholder Relations, +46 72 989 09 15
EQT Shareholder Relations, [email protected]

Rickard Buch, Head of Corporate Communications, +46 72 989 09 11
EQT Press Office, [email protected], +46 8 506 55 334

This information was brought to you by Cision,c3956826

The following files are available for download:

Invitation to presentation of EQT AB’s Q1 Announcement 2024,c3285895

EQT AB Group


View original content:

Continue Reading

Fintech PR

Kia presents roadmap to lead global electrification era through EVs, HEVs and PBVs



  • Kia drives forward transformation into ‘Sustainable Mobility Solutions Provider’
  • Roadmap enables Kia to proactively respond to uncertainties in mobility industry landscape, including changes in EV market
  • Company to expand EV line-up with more models; enhance HEV line-up to manage fluctuation in EV demand
    • Goal to sell 1.6 million EVs annually in 2030, introducing 15 models
    • PBV to play a key role in Kia’s growth, targeting 250,000 PBV sales annually by 2030 with PV5 and PV7 models
  • Kia to invest KRW 38 trillion by 2028, including KRW 15 trillion for future business
  • 2024 business guidance : KRW 101 tln in revenue with KRW 12 tln in operating profit; operating profit margin of 11.9% on sales of 3.2 million units globally
  • CEO reaffirms Kia’s commitment to ESG management

SEOUL, South Korea, April 5, 2024 /PRNewswire/ — Kia Corporation (Kia) today shared an update on its future strategies and financial targets at its CEO Investor Day in Seoul, Korea.

Based on its innovative achievements in the years since the announcement of mid-to-long-term business initiatives, Kia is focusing on updating its 2030 strategy announced last year and further strengthening its business strategy in response to uncertainties across the global mobility industry landscape.

During the event, Kia updated its mid-to-long-term business strategy with a focus on electrification, and its PBV business. Kia reiterated its 2030 annual sales target of 4.3 million units, including 1.6 million units of electric vehicles (EVs). The 2030 4.3 million annual sales target is 34.4 percent higher than the brand’s 2024 annual goal of 3.2 million units.

The company also plans to become a leading EV brand by selling a higher percentage of electrified models among its total sales, including hybrid electric vehicles (HEV), plug-in hybrid (PHEV), and battery EVs, projecting electrified model sales of 2.48 million units annually or 58 percent of Kia’s total sales in 2030.

“Following our successful brand relaunch in 2021, Kia is enhancing its global business strategy to further the establishment of an innovative EV line-up and accelerate the company’s transition to a sustainable mobility solutions provider,” said Ho Sung Song, President and CEO of Kia. “By responding effectively to changes in the mobility market and efficiently implementing mid-to-long-term strategies, Kia is strengthening its brand commitment to the wellbeing of customers, communities, the global society, and the environment.”

Photo –

Cision View original content to download multimedia:

Continue Reading

Fintech PR

BioVaxys Technology Corp. Provides Bi-Weekly MCTO Status Update




VANCOUVER, BC, April 4, 2024 /PRNewswire/ — BioVaxys Technology Corp. (CSE: BIOV) (FRA: 5LB) (OTCQB: BVAXF) (the “Company“) is providing this bi-weekly update on the status of the management cease trade order granted on February 29, 2024 (the “MCTO“), by its principal regulator, the Ontario Securities Commission (the “OSC“), under National Policy 12-203 – Management Cease Trade Orders (“NP 12-203“), following the Company’s announcement on February 21, 2024 (the “Default Announcement“), that it was unable to file its audited annual financial statements for the year ended October 31, 2023, its management’s discussion and analysis of financial statements for the year ended October 31, 2023, its annual information form for the year ended October 31, 2023, and related filings (collectively, the “Required Annual Filings“). Under National Instrument 51-102, the Required Annual Filings were required to be made no later than February 28, 2024.

As a result of the delay in filing the Required Annual Filings, the Company was unable to file its interim financial statements for the three months ended January 31, 2024, its management’s discussion and analysis of financial statements for the three months ended January 31, 2024, and related filings (collectively, the “Required Interim Filings“). Under National Instrument 51-102, the Required Interim Filings were required to be made no later than April 1, 2024.

The Company anticipates filing the Required Annual Filings by April 30, 2024. The auditor of the Company requires additional time to complete its audit of the Company, including the Company’s recent acquisition of all intellectual property, immunotherapeutics platform technologies, and clinical stage assets of the former IMV Inc. that closed on February 16, 2024. In addition, the Company anticipates filing the Required Interim Filings immediately after the filing of the Required Annual Filings.

Except as herein disclosed, there are no material changes to the information contained in the Default Announcement. In addition, (i) the Company is satisfying and confirms that it intends to continue to satisfy the provisions of the alternative information guidelines under NP 12-203 and issue bi-weekly default status reports for so long as the delay in filing the Required Annual Filings and/or Required Interim Filings is continuing, each of which will be issued in the form of a press release; (ii) the Company does not have any information at this time regarding any anticipated specified default subsequent to the default in filing the Required Annual Filings and Required Interim Filings; (iii) the Company is not subject to any insolvency proceedings; and (iv) there is no material information concerning the affairs of the Company that has not been generally disclosed.

About BioVaxys Technology Corp.

BioVaxys Technology Corp. (, a biopharmaceuticals company registered in British Columbia, Canada, is a clinical-stage biopharmaceutical company dedicated to improving patient lives with novel immunotherapies based on the DPX™ immune-educating technology platform and it’s HapTenix© ‘neoantigen’ tumor cell construct platform, for treating cancers, infectious disease, antigen desensitization, and other immunological fields. The Company’s clinical stage pipeline includes maveropepimut-S which is in Phase II clinical development for advanced Relapsed-Refractory Diffuse Large B Cell Lymphoma (DLBCL) and platinum resistant ovarian cancer, and BVX-0918, a personalized immunotherapeutic vaccine using it proprietary HapTenix© ‘neoantigen’ tumor cell construct platform which is soon to enter Phase I in Spain for treating refractive late-stage ovarian cancer. The Company is also capitalizing on its tumor immunology know-how and creation of a unique library of T-lymphocytes & other datasets post-vaccination with its personalized immunotherapeutic vaccines to utilize predictive algorithms and other technologies to identify new targetable tumor antigens. BioVaxys common shares are listed on the CSE under the stock symbol “BIOV” and trade on the Frankfurt Bourse (FRA: 5LB) and in the US (OTCQB: BVAXF). For more information, visit and connect with us on X and LinkedIn.


Signed “James Passin
James Passin, Chief Executive Officer
Phone: +1 646 452 7054

Logo –

Cision View original content:

Continue Reading